Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SELP | P16109 | 2/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442601 | 0.93 | ABCB1 (0.68) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL3828912 | 0.91 | ABCB1 (0.69) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL13679699 | 0.86 | ABCB1 (0.92) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL3830858 | 0.86 | ABCB1 (0.92) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL6625154 | 0.84 | ABCB1 (0.69) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL16448288 | 0.83 | ABCB1 (0.68) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL718305 | 0.83 | ABCB1 (0.68) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL13679647 | 0.82 | ABCB1 (0.53) | ABCB1NOX1MAPT | |
| SCHEMBL719051 | 0.81 | ABCB1 (0.74) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL3826448 | 0.81 | ABCB1 (1.00) | ABCB1NOX1PTPN1ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | TAIJI BIOMEDICAL, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9023845-B2 | Compositions and methods for treating lysosomal disorders | NEURALTUS PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | disclosed |
| US-8252789-B2 | Compositions and methods for treating lysosomal disorders | NEURALTUS PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | disclosed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2211856-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | The Hospital For Sick Children (CA) | 2010-08-04 | — | — | EP | disclosed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1221847-A4 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1221847-A1 | METHODS OF ENHANCING CHEMOTHERAPY | Ontogen Corporation (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001026467-A1 | METHODS OF ENHANCING CHEMOTHERAPY | ONTOGEN CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ABCB1 3788/4885NOX1 1373/4885PTPN1 2752/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ABCB1 3602/4885NOX1 1268/4885PTPN1 2752/4885 |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | GAA, GBA1, LIPA | ABCB1 1406/4885NOX1 3537/4885PTPN1 4036/4885 |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885NOX1 3939/4885PTPN1 3797/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | ABCB1 14/4885NOX1 4001/4885PTPN1 3854/4885 |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | ABCB1 1406/4885NOX1 3537/4885PTPN1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.